Ministry of Health and Long Term Care

Ontario Public Drug Programs
Drug Submission Status

Generic Name: fluticasone propionate & azelastine HCl

Brand Name: Dymista

Strength: 50mcg & 137mcg (per actuation) spray, metered dose (nasal)

Manufacturer: Meda Pharmaceuticals Ltd.

Indication: Symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptomsin adults and adolescents aged 12 years and older for whom monotherapy with either antihistamines or intranasal corticosteroids is not considered sufficient.

Rapid Review: Not Requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Status:
First Review: (Initial Submission)	28/05/2015	27/07/2015	EO decision rendered	Funding not considered through Ontario Public Drug Programs

Rapid Review:

Details of the Rapid Review process can be found at:

Rapid Review Process

Review Status:

- Screening - Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.

Ontario

- Submission incomplete - Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review - Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed - A recommendation was made by the CED.
- Ontario Steering Committee for Cancer Drugs (OSCCD) review completed-A recommendation was made by the OSCCD.
- Executive Officer (EO) decision rendered.

Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

The CED recommendation and the EO decision

Updated: November 24, 2015